SCHEMBL1887819

SCHEMBL1887819

CCc1c(C(=O)O)cc(C(C)C)n1Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.51
TSHR P16473 2/20 0.43
FABP4 P15090 1/20 0.43
PLA2G2A P14555 6/20 0.42
CCR2 P41597 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
NR4A3 Q92570 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PLA2G10 O15496 1/20 0.40
PLA2G1B P04054 1/20 0.40
PLA2G5 P39877 1/20 0.40
PLA2G2F Q9BZM2 1/20 0.40
PLA2G2E Q9NZK7 1/20 0.40
PLA2G2D Q9UNK4 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884680 0.89 NOTUM (0.51) NOTUMTSHRFABP4CCR2SMN1; SMN2
SCHEMBL1890367 0.87 GAA (0.48) TSHRPLA2G2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL1884573 0.87 NOTUM (0.47) NOTUM
SCHEMBL12672207 0.83 NOTUM (0.49) NOTUMTSHRFABP4CCR2SMN1; SMN2
SCHEMBL1875610 0.83 NOTUM (0.46) NOTUMTSHRFABP4CCR2SMN1; SMN2
SCHEMBL1875953 0.82 NOTUM (0.70) NOTUMTSHRFABP4CCR2SMN1; SMN2
SCHEMBL1873898 0.82 NOTUM (0.54) NOTUMTSHRFABP4CCR2SMN1; SMN2
SCHEMBL1880517 0.76 MAPT (0.47) NOTUMTSHRSMN1; SMN2KDM4EALDH1A1
SCHEMBL1887533 0.75 MAPK8 (0.50) TSHRSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL2745695 0.73 CNR1 (0.56) NOTUMTSHRFABP4PLA2G2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity ALLERGAN, INC. (US) 2011-05-05 US disclosed
EP-2185506-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2010-05-19 EP disclosed
WO-2009026407-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity S1PR1, S1PR2, S1PR3 NOTUM 822/4885TSHR 296/4885FABP4 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.